Achillion Pharmaceut (ACHN) 8.23 $ACHN
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu Sep 01, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
ACHN: 8.23 (-0.03)
Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
PR Newswire - Tue Aug 23, 6:40AM CDT
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
HALO: 9.97 (+0.17), CMRX: 4.62 (-0.19), ACHN: 8.23 (-0.03), AEGR: 1.59 (-0.04)
Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Achillion Pharmaceuticals (ACHN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ACHN: 8.23 (-0.03)
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
GlobeNewswire - Thu Aug 11, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to evaluate all-oral combination regimens, containing odalasvir, AL-335 and simeprevir, were accepted for presentation at the EASL - American Association for the Study of Liver Diseases (AASLD) Special Conference: New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, being hosted in Paris, France on September 23 - 24, 2016.
JNJ: 119.08 (-0.26), ACHN: 8.23 (-0.03)
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 09, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 10:55am EDT at the Le Parker Meridien Hotel in New York City, NY.
ACHN: 8.23 (-0.03)
Achillion Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:12PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second quarter of 2016, Achillion reported a net loss of $18.5 million or $0.14 per share, compared with a net loss of $29.0 million or $0.25 per share for the second quarter of 2015. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2016 were $426.5 million.
ACHN: 8.23 (-0.03)
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 8.23 (-0.03)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.23 (-0.03), JAZZ: 123.31 (-0.52), GRFS: 15.90 (-0.01), PBYI: 58.71 (-0.44)
Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 8.23 (-0.03)
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 8.23 (-0.03)
Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 8.23 (-0.03)
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 8.23 (-0.03)
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 8.23 (-0.03), DB: 14.69 (-0.06)
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 8.23 (-0.03)
First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 8.23 (-0.03)
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 8.23 (-0.03), AVXS: 34.53 (-0.81)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 119.08 (-0.26), INO: 9.14 (-0.03), ACHN: 8.23 (-0.03), GSK: 42.98 (-0.48), NVS: 78.27 (-0.50), CELGZ: 1.13 (-0.03)
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 119.08 (-0.26), GILD: 77.42 (-0.96), ACHN: 8.23 (-0.03), BMY: 56.76 (-0.63)
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 8.23 (-0.03)
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Thu Sep 01, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
ACHN: 8.23 (-0.03)
Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
PR Newswire - Tue Aug 23, 6:40AM CDT
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
HALO: 9.97 (+0.17), CMRX: 4.62 (-0.19), ACHN: 8.23 (-0.03), AEGR: 1.59 (-0.04)
Is Achillion Pharmaceuticals (ACHN) Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 7:34AM CDT
Achillion Pharmaceuticals (ACHN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
ACHN: 8.23 (-0.03)
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
GlobeNewswire - Thu Aug 11, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to evaluate all-oral combination regimens, containing odalasvir, AL-335 and simeprevir, were accepted for presentation at the EASL - American Association for the Study of Liver Diseases (AASLD) Special Conference: New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure, being hosted in Paris, France on September 23 - 24, 2016.
JNJ: 119.08 (-0.26), ACHN: 8.23 (-0.03)
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 09, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 10:55am EDT at the Le Parker Meridien Hotel in New York City, NY.
ACHN: 8.23 (-0.03)
Achillion Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:12PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second quarter of 2016, Achillion reported a net loss of $18.5 million or $0.14 per share, compared with a net loss of $29.0 million or $0.25 per share for the second quarter of 2015. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2016 were $426.5 million.
ACHN: 8.23 (-0.03)
Achillion Presents Interim Phase 1 Results for ACH-4471, a Novel Orally-Administered Factor D Inhibitor, at the 21st Congress of the European Hematology Association
GlobeNewswire - Fri Jun 10, 2:30AM CDT
- Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471 -
ACHN: 8.23 (-0.03)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.23 (-0.03), JAZZ: 123.31 (-0.52), GRFS: 15.90 (-0.01), PBYI: 58.71 (-0.44)
Achillion to Present at Three Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:02PM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences:
ACHN: 8.23 (-0.03)
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 5:05AM CDT
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers -
ACHN: 8.23 (-0.03)
Achillion reports 1Q loss
Automated Insights - Tue May 03, 5:19AM CDT
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $18.1 million in its first quarter.
ACHN: 8.23 (-0.03)
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs
GlobeNewswire - Tue May 03, 5:05AM CDT
- Company provides update on HCV collaboration with Janssen; Phase 2b combination study evaluating doublet and triplet regimens for six and eight weeks anticipated to begin in Q3 2016 -
ACHN: 8.23 (-0.03)
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference
GlobeNewswire - Thu Apr 28, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 41 Annual Health Care Conference on Thursday, May 5, 2016 at 1:30 p.m. EDT at The InterContinental Hotel in Boston, MA.
ACHN: 8.23 (-0.03), DB: 14.69 (-0.06)
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:02AM CDT
Investors certainly have to be happy with Achillion Pharmaceuticals, Inc. (ACHN) and its short term performance
ACHN: 8.23 (-0.03)
First Week of December 16th Options Trading For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Tue Apr 19, 9:57AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available this week, for the December 16th expiration.
ACHN: 8.23 (-0.03)
ObsEva Strengthens Board with Appointment of Biotechnology Veteran Dr. Frank Verwiel
GlobeNewswire - Thu Mar 24, 7:09AM CDT
ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced the appointment of Frank Verwiel, MD to its Board of Directors. Over the last 25 years, Dr. Verwiel has amassed a wealth of knowledge across multiple operational, development, and commercial disciplines for both small and large biotechnology and pharmaceutical companies. Most recently, Dr. Verwiel was President and Chief Executive Officer of Aptalis Pharma, Inc. (formerly Axcan Pharma Inc.), which was acquired by Forest Laboratories for $2.9 billion in 2014.
ACHN: 8.23 (-0.03), AVXS: 34.53 (-0.81)
Tuberculosis Therapeutics Development Pipeline Review, H2 2015 Featuring 60 Key Companies
M2 - Fri Feb 05, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/b2fbvp/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Tuberculosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tuberculosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Tuberculosis Overview - Therapeutics Development - Pipeline Products for Tuberculosis - Overview - Pipeline Products for Tuberculosis - Comparative Analysis - Tuberculosis - Therapeutics under Development by Companies - Tuberculosis - Therapeutics under Investigation by Universities/Institutes - Tuberculosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Tuberculosis - Products under Development by Companies - Tuberculosis - Products under Investigation by Universities/Institutes - Tuberculosis - Companies Involved in Therapeutics Development - Abera Bioscience AB - Achillion Pharmaceuticals, Inc. - BioDiem Ltd - BioLingus AG - Biomar Microbial Technologies - Bioversys AG - Celgene Corporation - Cellceutix Corporation - Chongqing Zhifei Biological Products Co., Ltd. - Ensol Biosciences Inc. - EpiVax, Inc. - FIT Biotech Oy - GangaGen Inc. - GlaxoSmithKline Plc - Globeimmune, Inc. - Hsiri Therapeutics, LLC - Imaxio SA - Immunitor, Inc. - ImmunoBiology Limited - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Lipotek Pty Ltd. - Microbion Corporation - Microbiotix, Inc. - NEARMEDIC PLUS, Ltd - Novartis AG - Okklo Life Sciences BV - Orchid Chemicals & Pharmaceuticals Ltd - Otsuka Holdings Co., Ltd. - Polymun Scientific Immunbiologische Forschung GmbH - Prokarium Limited - QureTech Bio AB - Sanofi - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/b2...berculosis
JNJ: 119.08 (-0.26), INO: 9.14 (-0.03), ACHN: 8.23 (-0.03), GSK: 42.98 (-0.48), NVS: 78.27 (-0.50), CELGZ: 1.13 (-0.03)
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 04, 2:40PM CST
Image source: Achillion Pharmaceuticals. W hat: Despite announcing a key new hire last month, shares in the clinical-stage drugmaker Achillion Pharmaceuticals dropped 37.3% in January, according to S&P Capital IQ. So what: On Jan....
JNJ: 119.08 (-0.26), GILD: 77.42 (-0.96), ACHN: 8.23 (-0.03), BMY: 56.76 (-0.63)
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of Regulatory Affairs
GlobeNewswire - Wed Feb 03, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the addition of two members to the senior management team. Martha Manning, Esq., joins Achillion as Executive Vice President, General Counsel and Secretary effective February 1, 2016. In addition, Amy Jennings, Ph.D., recently joined the Company and will serve as Senior Vice President of Regulatory Affairs.
ACHN: 8.23 (-0.03)
